Karyotype complexity and prognosis in acute myeloid leukemia

A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that diff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Stölzel, Friedrich (VerfasserIn) , Bochtler, Tilmann (VerfasserIn) , Krämer, Alwin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 January 2016
In: Blood cancer journal
Year: 2016, Jahrgang: 6, Heft: 1, Pages: 1-7
ISSN:2044-5385
DOI:10.1038/bcj.2015.114
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bcj.2015.114
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bcj2015114
Volltext
Verfasserangaben:F. Stölzel, B. Mohr, M. Kramer, U. Oelschlägel, T. Bochtler, W.E. Berdel, M. Kaufmann, C.D. Baldus, K. Schäfer-Eckart, R. Stuhlmann, H. Einsele, S.W. Krause, H. Serve, M. Hänel, R. Herbst, A. Neubauer, K. Sohlbach, J. Mayer, J.M. Middeke, U. Platzbecker, M. Schaich, A. Krämer, C. Röllig, J. Schetelig, M. Bornhäuser and G. Ehninger
Beschreibung
Zusammenfassung:A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21∼22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with ⩾4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21∼22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.
Beschreibung:Gesehen am 15.05.2020
Beschreibung:Online Resource
ISSN:2044-5385
DOI:10.1038/bcj.2015.114